QUAD is marketed by MEDVi as a sublingual, four-drug cocktail for erectile dysfunction, combining three well-known PDE5 inhibitors—sildenafil, tadalafil, and…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
The digital health company MEDVi, recently spotlighted in an April 2 New York Times profile that depicted CEO Matthew Gallagher…
Read More
Long-Term Residential Exposure to Chlorpyrifos Increases Parkinson’s Disease Risk by Over Two and a Half Times UCLA Health Study Finds
A groundbreaking longitudinal study conducted by researchers at UCLA Health has established a definitive link between chronic residential exposure to…
Read More
